论文部分内容阅读
肝癌的导向治疗,自80年代以来发展较快,已成为肝癌综合治疗的手段之一.铁蛋白抗体和甲胎蛋白抗体的标记与治疗显示一定的效果,但作为一种剂型尚有差距.本文报道抗肝癌单抗HAbl8进入I期临床导向诊断、治疗的意义和应用情况。 抗体的纯化与标记,按Goding法,用杂交瘤腹水经Sephacryls-300层析柱纯化为IgG.再用胃蛋白酶(Sigma)切割,分
The therapeutic treatment of liver cancer has developed rapidly since the 1980s and has become one of the means for comprehensive treatment of liver cancer. The labeling and treatment of ferritin antibody and alpha fetoprotein antibody show a certain effect, but there is still a gap as a dosage form. The significance and application of anti-hepatocarcinoma HAbl8 in the clinical diagnosis and treatment of phase I were reported. Purification and labeling of antibodies, purification of ascites by hybridoma ascites on Sephacryls-300 column as IgG, and digestion with pepsin (Sigma).